Niklas Mattsson

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6647443/publications.pdf

Version: 2024-02-01

283	24,394	8172	9334
papers	citations	76 h-index	143 g-index

311	311	311	17827
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The BIN1 rs744373 Alzheimer's disease risk SNP is associated with faster AÎ²â€associated tau accumulation and cognitive decline. Alzheimer's and Dementia, 2022, 18, 103-115.	0.4	24
2	Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma AÎ²42/AÎ²40 and pâ€tau. Alzheimer's and Dementia, 2022, 18, 283-293.	0.4	72
3	Serum Neurofilament Light Chain as a Marker of Progression in Parkinsonâ€™s Disease: Long-Term Observation and Implications of Clinical Subtypes. Journal of Parkinson's Disease, 2022, 12, 571-584.	1.5	13
4	Central nervous system monoaminergic activity in hip osteoarthritis patients with disabling pain: associations with pain severity and central sensitization. Pain Reports, 2022, 7, e988.	1.4	8
5	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. JAMA Neurology, 2022, 79, 228.	4.5	97
6	Association of Î²-Amyloid Accumulation With Executive Function in Adults With Unimpaired Cognition. Neurology, 2022, 98, .	1.5	22
7	Development of Apathy, Anxiety, and Depression in Cognitively Unimpaired Older Adults: Effects of Alzheimerâ€™s Disease Pathology and Cognitive Decline. Biological Psychiatry, 2022, 92, 34-43.	0.7	21
8	Components of gait in people with and without mild cognitive impairment. Gait and Posture, 2022, 93, 83-89.	0.6	7
9	Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease. JAMA Neurology, 2022, 79, 149.	4.5	66
10	Cerebrospinal Fluid Biomarkers in Autopsy-Confirmed Alzheimer Disease and Frontotemporal Lobar Degeneration. Neurology, 2022, 98, .	1.5	49
11	Serum neurofilament light levels are correlated to long-term neurocognitive outcome measures after cardiac arrest. Brain Injury, 2022, 36, 800-809.	0.6	7
12	Association of CSF AÎ² ₃₈ Levels With Risk of Alzheimer Diseaseâ€“Related Decline. Neurology, 2022, 98, .	1.5	16
13	Bloodâ€based biomarkers for Alzheimer's disease. EMBO Molecular Medicine, 2022, 14, e14408.	3.3	122
14	Association Between EEG Patterns and Serum Neurofilament Light After Cardiac Arrest. Neurology, 2022, 98, .	1.5	7
15	Astrocytic function is associated with both amyloid-Î² and tau pathology in non-dementedAPOE Ïµ4carriers. Brain Communications, 2022, 4, .	1.5	4
16	Î²-Amyloidâ€“Dependent and â€“Independent Genetic Pathways Regulating CSF Tau Biomarkers in Alzheimer Disease. Neurology, 2022, 99, .	1.5	3
17	Association of Enlarged Perivascular Spaces and Measures of Small Vessel and Alzheimer Disease. Neurology, 2021, 96, e193-e202.	1.5	54
18	The Effects of Tau, Amyloid, and White Matter Lesions on Mobility, Dual Tasking, and Balance in Older People. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2021, 76, 683-691.	1.7	8

#	Article	IF	Citations
19	Association Between Apolipoprotein E Îµ2 vs Îµ4, Age, and Î²-Amyloid in Adults Without Cognitive Impairment. JAMA Neurology, 2021, 78, 229.	4.5	28
20	Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations. Nature Aging, 2021, 1, 114-123.	5.3	94
21	Plasma phosphorylated tau181 and neurodegeneration in Alzheimerâ€™s disease. Annals of Clinical and Translational Neurology, 2021, 8, 259-265.	1.7	25
22	Untangling the association of amyloid-Î² and tau with synaptic and axonal loss in Alzheimerâ€™s disease. Brain, 2021, 144, 310-324.	3.7	123
23	Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease. JAMA Neurology, 2021, 78, 149.	4.5	176
24	The impact of demographic, clinical, genetic, and imaging variables on tau PET status. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2245-2258.	3.3	27
25	Current advances in plasma and cerebrospinal fluid biomarkers in Alzheimer's disease. Current Opinion in Neurology, 2021, 34, 266-274.	1.8	54
26	Mild behavioral impairment and its relation to tau pathology in preclinical Alzheimerâ€™s disease. Translational Psychiatry, 2021, 11, 76.	2.4	78
27	Accelerated inflammatory aging in Alzheimerâ€™s disease and its relation to amyloid, tau, and cognition. Scientific Reports, 2021, 11, 1965.	1.6	28
28	Time between milestone events in the Alzheimer's disease amyloid cascade. NeuroImage, 2021, 227, 117676.	2.1	20
29	Preoperative sleep quality and adverse pain outcomes after total hip arthroplasty. European Journal of Pain, 2021, 25, 1482-1492.	1.4	25
30	Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment. Alzheimer's Research and Therapy, 2021, 13, 68.	3.0	117
31	Early stages of tau pathology and its associations with functional connectivity, atrophy and memory. Brain, 2021, 144, 2771-2783.	3.7	78
32	Perceived walking difficulties in Parkinsonâ€™s disease â€“ predictors and changes over time. BMC Geriatrics, 2021, 21, 221.	1.1	8
33	A multicenter comparison of [18F]flortaucipir, [18F]RO948, and [18F]MK6240 tau PET tracers to detect a common target ROI for differential diagnosis. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2295-2305.	3.3	41
34	Prediction of future Alzheimerâ€™s disease dementia using plasma phospho-tau combined with other accessible measures. Nature Medicine, 2021, 27, 1034-1042.	15.2	236
35	Soluble Pâ€²tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau. EMBO Molecular Medicine, 2021, 13, e14022.	3.3	90
36	Plasma markers predict changes in amyloid, tau, atrophy and cognition in non-demented subjects. Brain, 2021, 144, 2826-2836.	3.7	65

#	Article	IF	Citations
37	Plasma biomarkers of Alzheimerâ€™s disease improve prediction of cognitive decline in cognitively unimpaired elderly populations. Nature Communications, 2021, 12, 3555.	5.8	115
38	Tau PET correlates with different Alzheimerâ€™s diseaseâ€related features compared to CSF and plasma pâ€tau biomarkers. EMBO Molecular Medicine, 2021, 13, e14398.	3.3	58
39	Plasma GFAP is an early marker of amyloid-Î² but not tau pathology in Alzheimerâ€™s disease. Brain, 2021, 144, 3505-3516.	3.7	198
40	Decreased pain sensitivity and alterations of cerebrospinal fluid and plasma inflammatory mediators after total hip arthroplasty in patients with disabling osteoarthritis. Pain Practice, 2021, , .	0.9	5
41	Serum markers of brain injury can predict good neurological outcome after out-of-hospital cardiac arrest. Intensive Care Medicine, 2021, 47, 984-994.	3.9	50
42	Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease. JAMA Neurology, 2021, 78, 961.	4.5	148
43	Comparing the Clinical Utility and Diagnostic Performance of CSF P-Tau181, P-Tau217, and P-Tau231 Assays. Neurology, 2021, 97, e1681-e1694.	1.5	60
44	Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. Lancet Neurology, The, 2021, 20, 739-752.	4.9	220
45	Comparing ATN-T designation by tau PET visual reads, tau PET quantification, and CSF PTau181 across three cohorts. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2259-2271.	3.3	10
46	The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, 1145-1156.	0.4	174
47	Genetic effects on longitudinal cognitive decline during the early stages of Alzheimerâ€™s disease. Scientific Reports, 2021, 11, 19853.	1.6	6
48	Ability of tauâ€PET, phosphoâ€tau217, NfL and cortical thickness to predict shortâ€term cognitive decline in early symptomatic Alzheimerâ€™s disease. Alzheimer's and Dementia, 2021, 17, .	0.4	0
49	Unravelling drivers of ageâ€and betaâ€amyloidâ€related neurodegeneration in medial temporal lobe atrophy in cognitively normal older adults. Alzheimer's and Dementia, 2021, 17, .	0.4	0
50	Plasma biomarkers predict longitudinal amyloid accumulation, tau burden, brain atrophy and cognitive decline in early Alzheimerâ€™s disease. Alzheimer's and Dementia, 2021, 17, .	0.4	0
51	Comparing the clinical utility and diagnostic performance of cerebrospinal fluid Pâ€tau181, Pâ€tau217 and Pâ€tau231 assays. Alzheimer's and Dementia, 2021, 17, .	0.4	0
52	Amyloidâ€Î² accumulation is independently related to executive function in cognitively unimpaired adults. Alzheimer's and Dementia, 2021, 17, .	0.4	0
53	Associations between longitudinal neuropsychiatric symptoms and biomarkers of betaâ€amyloid, tau, neurodegeneration, and cognitive decline. Alzheimer's and Dementia, 2021, 17, .	0.4	1
54	Potential drivers of ageâ€and betaâ€amyloidâ€related neurodegeneration in early and late Alzheimerâ€™s Disease regions in cognitively normal older adults. Alzheimer's and Dementia, 2021, 17, .	0.4	0

#	Article	IF	Citations
55	Prediction of future Alzheimerâ€™s disease dementia using plasma phosphoâ€tau combined with other accessible measures. Alzheimer's and Dementia, 2021, 17, .	0.4	2
56	Genetic influence during the early phases of Alzheimer's disease on longitudinal cognitive impairment.. Alzheimer's and Dementia, 2021, 17 Suppl 3, e053474.	0.4	0
57	Genetic interaction study of Alzheimer's disease quantitative biomarkers: A polygenic risk score analysis and evaluation.. Alzheimer's and Dementia, 2021, 17 Suppl 3, e053556.	0.4	0
58	Apathy and anxiety are early markers of Alzheimer's disease. Neurobiology of Aging, 2020, 85, 74-82.	1.5	103
59	Cerebrospinal Fluid Levels of Neurogranin in Parkinsonian Disorders. Movement Disorders, 2020, 35, 513-518.	2.2	22
60	Longitudinal plasma p-tau217 is increased in early stages of Alzheimerâ€™s disease. Brain, 2020, 143, 3234-3241.	3.7	150
61	Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. JAMA - Journal of the American Medical Association, 2020, 324, 772.	3.8	640
62	Comparing progression biomarkers in clinical trials of early Alzheimerâ€™s disease. Annals of Clinical and Translational Neurology, 2020, 7, 1661-1673.	1.7	27
63	Differential expression of cerebrospinal fluid neuroinflammatory mediators depending on osteoarthritis pain phenotype. Pain, 2020, 161, 2142-2154.	2.0	11
64	Comparison of 18 Fâ€Flortaucipir visual assessment, SUVR quantification and CSF pTau for defining Tâ€status in the AT(N) framework. Alzheimer's and Dementia, 2020, 16, e037276.	0.4	0
65	White matter lesions are associated with CSF biomarkers of neuroinflammation in prodromal Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e041795.	0.4	1
66	Mild behavioral impairment is predictive of tau deposition in the earliest stages of Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e042595.	0.4	6
67	Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies. Nature Communications, 2020, 11, 6252.	5.8	36
68	CDH6 and HAGH protein levels in plasma associate with Alzheimerâ€™s disease in APOE Îµ4 carriers. Scientific Reports, 2020, 10, 8233.	1.6	17
69	Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders. JAMA Neurology, 2020, 77, 955.	4.5	136
70	The implications of different approaches to define AT(N) in Alzheimer disease. Neurology, 2020, 94, e2233-e2244.	1.5	80
71	Relevance of biomarkers across different neurodegenerative diseases. Alzheimer's Research and Therapy, 2020, 12, 56.	3.0	42
72	Performance of a guideline-recommended algorithm for prognostication of poor neurological outcome after cardiac arrest. Intensive Care Medicine, 2020, 46, 1852-1862.	3.9	59

#	Article	IF	Citations
73	Plasma P-tau181 in Alzheimerâ€™s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimerâ€™s dementia. Nature Medicine, 2020, 26, 379-386.	15.2	643
74	Perspectives in fluid biomarkers in neurodegeneration from the 2019 biomarkers in neurodegenerative diseases courseâ€"a joint PhD student course at University College London and University of Gothenburg. Alzheimer's Research and Therapy, 2020, 12, 20.	3.0	32
75	Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimerâ€™s disease. Nature Communications, 2020, 11, 1683.	5.8	252
76	AÎ² deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimerâ€™s disease. Science Advances, 2020, 6, eaaz2387.	4.7	202
77	Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurology, The, 2020, 19, 422-433.	4.9	668
78	The A4 study: Î²â€amyloid and cognition in 4432 cognitively unimpaired adults. Annals of Clinical and Translational Neurology, 2020, 7, 776-785.	1.7	43
79	Utility of plasma neurofilament light and total tau for clinical trials in Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12099.	1.2	16
80	Serum GFAP and UCH-L1 for the prediction of neurological outcome in comatose cardiac arrest patients. Resuscitation, 2020, 154, 61-68.	1.3	37
81	The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects. Brain, 2020, 143, 3805-3815.	3.7	65
82	Acute reduction of cerebrospinal fluid volume prior to spinal anesthesia: implications for sensory block extent. Minerva Anestesiologica, 2020, 86, 636-644.	0.6	3
83	Cerebrospinal fluid neurofilament light is associated with survival in mitochondrial disease patients. Mitochondrion, 2019, 46, 228-235.	1.6	10
84	Î²-amyloid pathology and hippocampal atrophy are independently associated with memory function in cognitively healthy elderly. Scientific Reports, 2019, 9, 11180.	1.6	28
85	Determining clinically meaningful decline in preclinical Alzheimer disease. Neurology, 2019, 93, e322-e333.	1.5	96
86	Staging Î²-Amyloid Pathology With Amyloid Positron Emission Tomography. JAMA Neurology, 2019, 76, 1319.	4.5	149
87	Associations among amyloid status, age, and longitudinal regional brain atrophy in cognitively unimpaired older adults. Neurobiology of Aging, 2019, 82, 110-119.	1.5	11
88	Primary fatty amides are potential plasma biomarkers for AD. Nature Reviews Neurology, 2019, 15, 498-499.	4.9	0
89	Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease. EMBO Molecular Medicine, 2019, 11, e11170.	3.3	228
90	Multiplex proteomics identifies novel CSF and plasma biomarkers of early Alzheimerâ€™s disease. Acta Neuropathologica Communications, 2019, 7, 169.	2.4	146

#	Article	IF	Citations
91	Predicting diagnosis and cognition with ¹⁸Fâ€AVâ€1451 tau PET and structural MRI in Alzheimer's disease. Alzheimer's and Dementia, 2019, 15, 570-580.	0.4	84
92	Associations between partial pressure of oxygen and neurological outcome in out-of-hospital cardiac arrest patients: an explorative analysis of a randomized trial. Critical Care, 2019, 23, 30.	2.5	33
93	Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology. JAMA Neurology, 2019, 76, 1035.	4.5	455
94	Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Diseaseâ€“Related Î²-Amyloid Status. JAMA Neurology, 2019, 76, 1060.	4.5	282
95	Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease. JAMA Neurology, 2019, 76, 791.	4.5	436
96	Serum tau fragments as predictors of death or poor neurological outcome after out-of-hospital cardiac arrest. Biomarkers, 2019, 24, 584-591.	0.9	3
97	P4â€536: CEREBROSPINAL FLUID BIOMARKERS FOR AMYLOID AND TAU USING FULLY AUTOMATED ASSAYS: ASSOCIATIONS WITH NEUROPATHOLOGY. Alzheimer's and Dementia, 2019, 15, P1521.	0.4	0
98	DTâ€01â€04: DIAGNOSTIC PERFORMANCE OF [¹⁸F]RO948 PET IN THE SEPARATION OF ALZHEIMER'S DISEASE FROM OTHER NEURODEGENERATIVE DISORDERS: FINDINGS FROM THE BIOFINDERâ€2 STUDY. Alzheimer's and Dementia, 2019, 15, P1485.	0.4	0
99	Predicting clinical decline and conversion to Alzheimerâ€™s disease or dementia using novel Elecsys AÎ²(1â€“42), pTau and tTau CSF immunoassays. Scientific Reports, 2019, 9, 19024.	1.6	123
100	Predictive Factors of Concerns about Falling in People with Parkinsonâ€™s Disease: A 3-Year Longitudinal Study. Parkinson's Disease, 2019, 2019, 1-9.	0.6	8
101	Associations between tau, AÎ², and cortical thickness with cognition in Alzheimer disease. Neurology, 2019, 92, e601-e612.	1.5	196
102	Dataâ€driven approaches for tauâ€PET imaging biomarkers in Alzheimer's disease. Human Brain Mapping, 2019, 40, 638-651.	1.9	27
103	Accurate risk estimation of Î²â€amyloid positivity to identify prodromal Alzheimer's disease: Crossâ€validation study of practical algorithms. Alzheimer's and Dementia, 2019, 15, 194-204.	0.4	49
104	Serum Neurofilament Light Chain for Prognosis of Outcome After Cardiac Arrest. JAMA Neurology, 2019, 76, 64.	4.5	158
105	Biomarkers for tau pathology. Molecular and Cellular Neurosciences, 2019, 97, 18-33.	1.0	163
106	The National Institute on Aging and the Alzheimer's Association Research Framework for Alzheimer's disease: Perspectives from the Research Roundtable. Alzheimer's and Dementia, 2018, 14, 563-575.	0.4	98
107	Amyloid pathology in the progression to mild cognitive impairment. Neurobiology of Aging, 2018, 64, 76-84.	1.5	27
108	Comparing ¹⁸ F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease. Neurology, 2018, 90, e388-e395.	1.5	83

#	Article	IF	Citations
109	Prevalence of the apolipoprotein E Îµ4 allele in amyloid Î² positive subjects across the spectrum of Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 913-924.	0.4	58
110	Fluid Biomarkers in Alzheimerâ€™s Disease and Frontotemporal Dementia. , 2018, , 221-252.		1
111	Apolipoprotein E genotypes and longevity across dementia disorders. Alzheimer's and Dementia, 2018, 14, 895-901.	0.4	8
112	Association of Cerebral Amyloid-Î² Aggregation With Cognitive Functioning in Persons Without Dementia. JAMA Psychiatry, 2018, 75, 84.	6.0	133
113	P1â€279: BIMODAL DISTRIBUTION OF THE CSF AÎ²42/AÎ²40 RATIO IN CLINICAL LABORATORY PRACTICE. Alzheimer's and Dementia, 2018, 14, P389.	0.4	0
114	DTâ€01â€06: COGNITIVE DECLINE IN PRECLINICAL ALZHEIMER'S DISEASE: A COMPARISON AND SYNTHESIS OF LARGE INTERNATIONAL COHORTS. Alzheimer's and Dementia, 2018, 14, P1667.	0.4	0
115	P1â€430: EFFECTS OF APOE Îµ4 ON TAU, AMYLOID, ATROPHY AND COGNITION IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P473.	0.4	0
116	DTâ€01â€01: DEVELOPMENT OF AB, TAU AND COGNITIVE CHANGES DURING THE TIME COURSE OF SPORADIC ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1665.	0.4	0
117	DTâ€02â€04: DETECTING BRAIN AMYLOID STATUS USING FULLY AUTOMATED PLASMA AÎ² BIOMARKER ASSAYS. Alzheimer's and Dementia, 2018, 14, P1670.	0.4	1
118	Prevalence of amyloidâ€Îβ pathology in distinct variants of primary progressive aphasia. Annals of Neurology, 2018, 84, 729-740.	2.8	132
119	Discriminative Accuracy of [¹⁸F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders. JAMA - Journal of the American Medical Association, 2018, 320, 1151.	3.8	298
120	Chronic depressive symptomatology and CSF amyloid beta and tau levels in mild cognitive impairment. International Journal of Geriatric Psychiatry, 2018, 33, 1305-1311.	1.3	16
121	The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review. Alzheimer's and Dementia, 2018, 14, 1313-1333.	0.4	87
122	CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease. Neurology, 2018, 91, e867-e877.	1.5	207
123	Effects of APOE Îµ4 on neuroimaging, cerebrospinal fluid biomarkers, and cognition in prodromal Alzheimer's disease. Neurobiology of Aging, 2018, 71, 81-90.	1.5	15
124	Greater tau load and reduced cortical thickness in APOE Îµ4-negative Alzheimerâ€™s disease: a cohort study. Alzheimer's Research and Therapy, 2018, 10, 77.	3.0	56
125	Carbon dioxide dynamics in relation to neurological outcome in resuscitated out-of-hospital cardiac arrest patients: an exploratory Target Temperature Management Trial substudy. Critical Care, 2018, 22, 196.	2.5	31
126	Cerebrospinal fluid neurofilament light concentration in motor neuron disease and frontotemporal dementia predicts survival. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 397-403.	1.1	58

#	Article	IF	Citations
127	Cortical Atrophy is Associated with Accelerated Cognitive Decline in Mild Cognitive Impairment with Subsyndromal Depression. American Journal of Geriatric Psychiatry, 2017, 25, 980-991.	0.6	26
128	Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease. JAMA Neurology, 2017, 74, 557.	4.5	664
129	Clinical validity of cerebrospinal fluid AÎ²42, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. Neurobiology of Aging, 2017, 52, 196-213.	1.5	100
130	Earliest accumulation of Î²-amyloid occurs within the default-mode network and concurrently affects brain connectivity. Nature Communications, 2017, 8, 1214.	5.8	596
131	Serum tau and neurological outcome in cardiac arrest. Annals of Neurology, 2017, 82, 665-675.	2.8	86
132	A novel quantification-driven proteomic strategy identifies an endogenous peptide of pleiotrophin as a new biomarker of Alzheimerâ€™s disease. Scientific Reports, 2017, 7, 13333.	1.6	45
133	[O2â€“05â€“05]: EFFECTS OF APOE E4 IN PRODROMAL ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P562.	0.4	0
134	CSF/serum albumin ratio in dementias: a cross-sectional study on 1861 patients. Neurobiology of Aging, 2017, 59, 1-9.	1.5	84
135	¹⁸Fâ€AVâ€1451 and CSF Tâ€tau and Pâ€tau as biomarkers in Alzheimer's disease. EMBO Molecular Medicine, 2017, 9, 1212-1223.	3.3	156
136	Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers. Lancet Neurology, The, 2017, 16, 661-676.	4.9	464
137	Ex vivo 18O-labeling mass spectrometry identifies a peripheral amyloid Î² clearance pathway. Molecular Neurodegeneration, 2017, 12, 18.	4.4	17
138	Multiple comorbid neuropathologies in the setting of Alzheimer's disease neuropathology and implications for drug development. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 83-91.	1.8	94
139	[P3â€“132]: CSF BIOMARKERS OF NEUROINFLAMMATION ARE ELEVATED IN PRECLINICAL AND PRODROMAL AD AND CORRELATE WITH TAU PATHOLOGY. Alzheimer's and Dementia, 2017, 13, P985.	0.4	0
140	[P4â€“197]: EMERGING AMYLOID PATHOLOGY. Alzheimer's and Dementia, 2017, 13, P1340.	0.4	0
141	[P1â€“575]: PREVALENCE OF THE APOLIPOPROTEIN E Îµ4 ALLELE IN AMYLOIDâ€Î²2 POSITIVE SUBJECTS ACROSS THE SPECTRUM OF ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P515.	0.4	0
142	[P3â€“075]: PLEIOTROPHIN, A NEW BIOMARKER FOR AD, IDENTIFIED USING A NOVEL STRATEGY IN CLINICAL PROTEOMICS. Alzheimer's and Dementia, 2017, 13, P960.	0.4	0
143	Time to Amyloid Positivity and Preclinical Changes in Brain Metabolism, Atrophy, and Cognition: Evidence for Emerging Amyloid Pathology in Alzheimer's Disease. Frontiers in Neuroscience, 2017, 11, 281.	1.4	62
144	Effects of surgery and propofol-remifentanil total intravenous anesthesia on cerebrospinal fluid biomarkers of inflammation, Alzheimerâ€™s disease, and neuronal injury in humans: a cohort study. Journal of Neuroinflammation, 2017, 14, 193.	3.1	15

#	Article	IF	Citations
145	Preclinical effects of APOE Îµ4 on cerebrospinal fluid AÎ²42 concentrations. Alzheimer's Research and Therapy, 2017, 9, 87.	3.0	22
146	Reply: Do we still need positron emission tomography for early Alzheimerâ€™s disease diagnosis?. Brain, 2016, 139, e61-e61.	3.7	5
147	Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease. EMBO Molecular Medicine, 2016, 8, 1184-1196.	3.3	219
148	P4â€339: Earlyâ€•and Lateâ€Onset Alzheimerâ€™S Disease are Associated with Distinct Regional TAU Pathology as Examined with [18]Fâ€AVâ€1451 TAU Positron Emission Tomography. Alzheimer's and Dementia, 2016, 12, P1164.	0.4	0
149	P2-167: Roadmap to the Biomarker-Based Diagnosis of Alzheimer's Disease. , 2016, 12, P679-P680.		0
150	O1â€05â€01: Increased Amyloidogenic app Processing in Apoe E4â€Negative Individuals with Cerebral Bâ€Amyloidosis. Alzheimer's and Dementia, 2016, 12, P182.	0.4	0
151	ICâ€Pâ€002: : Roadmap to The Biomarkerâ€Based Diagnosis of Alzheimerâ€™s Disease. Alzheimer's and Dementia, 2016, 12, P13.	0.4	0
152	P2â€142: Comparison of Tâ€Tau, Neurogranin and NFL as CSF Neurodegeneration Markers in Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P667.	0.4	0
153	Cerebrospinal fluid analysis detects cerebral amyloid-Î² accumulation earlier than positron emission tomography. Brain, 2016, 139, 1226-1236.	3.7	292
154	Accelerating rates of cognitive decline and imaging markers associated with Î²-amyloid pathology. Neurology, 2016, 86, 1887-1896.	1.5	42
155	Cognitive and functional changes associated with AÎ² pathology and the progression to mild cognitive impairment. Neurobiology of Aging, 2016, 48, 172-181.	1.5	28
156	Plasma tau in Alzheimer disease. Neurology, 2016, 87, 1827-1835.	1.5	371
157	Assessing risk for preclinical Î²â€amyloid pathology with APOE, cognitive, and demographic information. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 4, 76-84.	1.2	49
158	Increased amyloidogenic APP processing in APOE É›4-negative individuals with cerebral Î²-amyloidosis. Nature Communications, 2016, 7, 10918.	5.8	48
159	Serum neurofilament light protein predicts clinical outcome in traumatic brain injury. Scientific Reports, 2016, 6, 36791.	1.6	281
160	Cerebrospinal fluid AÎ²42/AÎ²40 and AÎ²42/AÎ²38 as biomarkers of Alzheimerâ€™s disease. Neurobiology of Aging, 2016, 39, S28.	1.5	5
161	Cerebral amyloid burden and Alzheimer's disease subtypes â€“ does localization information matter?. European Journal of Neurology, 2016, 23, 233-234.	1.7	2
162	Chronic Depressive Symptomatology in Mild Cognitive Impairment Is Associated with Frontal Atrophy Rate which Hastens Conversion to Alzheimer Dementia. American Journal of Geriatric Psychiatry, 2016, 24, 126-135.	0.6	60

#	Article	IF	Citations
163	<scp>CSF</scp> AÎ²42/AÎ²40 and AÎ²42/AÎ²38 ratios: better diagnostic markers of Alzheimer disease. Annals of Clinical and Translational Neurology, 2016, 3, 154-165.	1.7	329
164	Total-tau and neurofilament light in CSF reflect spinal cord ischaemia after endovascular aortic repair. Neurochemistry International, 2016, 93, 1-5.	1.9	17
165	Selective vulnerability in neurodegeneration: insights from clinical variants of Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1000-1004.	0.9	62
166	Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression. JAMA Neurology, 2016, 73, 60.	4.5	354
167	Interaction of Cigarette Smoking History WithAPOEGenotype and Age on Amyloid Level, Glucose Metabolism, and Neurocognition in Cognitively Normal Elders. Nicotine and Tobacco Research, 2016, 18, 204-211.	1.4	30
168	Biomarkers and cognitive endpoints to optimize trials in Alzheimer's disease. Annals of Clinical and Translational Neurology, 2015, 2, 534-547.	1.7	32
169	Revolutionizing Alzheimer's disease and clinical trials through biomarkers. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 412-419.	1.2	80
170	S5-01-03: CSF biomarkers versus PET biomarkers. , 2015, 11, P302-P302.		0
171	Independent information from cerebrospinal fluid amyloid-Î² and florbetapir imaging in Alzheimer's disease. Brain, 2015, 138, 772-783.	3.7	200
172	Brain structure and function as mediators of the effects of amyloid on memory. Neurology, 2015, 84, 1136-1144.	1.5	44
173	Cerebrospinal fluid biomarkers and cerebral atrophy in distinct clinical variants of probable Alzheimer's disease. Neurobiology of Aging, 2015, 36, 2340-2347.	1.5	49
174	Cerebrospinal fluid tau and amyloid-Î²₁₋₄₂in patients with dementia. Brain, 2015, 138, 2716-2731.	3.7	152
175	Benchmarking biomarkerâ€based criteria for Alzheimer's disease: Data from the Swedish Dementia Registry, SveDem. Alzheimer's and Dementia, 2015, 11, 1470-1479.	0.4	17
176	Magnetic resonance imaging in Alzheimer's Disease Neuroimaging Initiative 2. Alzheimer's and Dementia, 2015, 11, 740-756.	0.4	142
177	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. JAMA - Journal of the American Medical Association, 2015, 313, 1924.	3.8	1,166
178	Predicting Reduction of Cerebrospinal Fluid Î²-Amyloid 42 in Cognitively Healthy Controls. JAMA Neurology, 2015, 72, 554.	4.5	42
179	The transitional association between Î²â€amyloid pathology and regional brain atrophy. Alzheimer's and Dementia, 2015, 11, 1171-1179.	0.4	37
180	CSF biomarkers for the differential diagnosis of Alzheimer's disease: A largeâ€scale international multicenter study. Alzheimer's and Dementia, 2015, 11, 1306-1315.	0.4	104

#	Article	IF	Citations
181	Amyloid biomarkers in Alzheimer's disease. Trends in Pharmacological Sciences, 2015, 36, 297-309.	4.0	404
182	Serum visinin-like protein-1 in concussed professional ice hockey players. Brain Injury, 2015, 29, 872-876.	0.6	25
183	Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease. Neurology, 2015, 85, 1240-1249.	1.5	288
184	Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimerâ€™s disease. Brain, 2015, 138, 3373-3385.	3.7	200
185	Î²-site amyloid precursor protein-cleaving enzyme 1(BACE1) inhibitor treatment induces AÎ²5-X peptides through alternative amyloid precursor protein cleavage. Alzheimer's Research and Therapy, 2014, 6, 75.	3.0	31
186	Reporting standards for studies of diagnostic test accuracy in dementia. Neurology, 2014, 83, 364-373.	1.5	182
187	Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease. Annals of Clinical and Translational Neurology, 2014, 1, 534-543.	1.7	96
188	Exploring Alzheimer Molecular Pathology in Down's Syndrome Cerebrospinal Fluid. Neurodegenerative Diseases, 2014, 14, 98-106.	0.8	44
189	Apolipoprotein E Genotype and the Diagnostic Accuracy of Cerebrospinal Fluid Biomarkers for Alzheimer Disease. JAMA Psychiatry, 2014, 71, 1183.	6.0	85
190	Diagnostic Performance of Cerebrospinal Fluid Total Tau and Phosphorylated Tau in Creutzfeldt-Jakob Disease. JAMA Neurology, 2014, 71, 476.	4.5	164
191	Emerging Î²-Amyloid Pathology and Accelerated Cortical Atrophy. JAMA Neurology, 2014, 71, 725.	4.5	51
192	CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival. Neurology, 2014, 83, 1945-1953.	1.5	213
193	Understanding the cause of sporadic Alzheimerâ€™s disease. Expert Review of Neurotherapeutics, 2014, 14, 621-630.	1.4	47
194	Cerebrospinal fluid biomarkers of Î²â€amyloid metabolism and neuronal damage in epileptic seizures. European Journal of Neurology, 2014, 21, 486-491.	1.7	21
195	Lysosomal Network Proteins as Potential Novel CSF Biomarkers for Alzheimerâ€™s Disease. NeuroMolecular Medicine, 2014, 16, 150-160.	1.8	89
196	Assessment of Peptide Chemical Modifications on the Development of an Accurate and Precise Multiplex Selected Reaction Monitoring Assay for Apolipoprotein E Isoforms. Journal of Proteome Research, 2014, 13, 1077-1087.	1.8	60
197	CSF in Alzheimer's Disease. Advances in Clinical Chemistry, 2014, 65, 143-172.	1.8	19
198	History of cigarette smoking in cognitively-normal elders is associated with elevated cerebrospinal fluid biomarkers of oxidative stress. Drug and Alcohol Dependence, 2014, 142, 262-268.	1.6	25

#	Article	IF	Citations
199	Cerebrospinal Fluid Î±-Synuclein and Lewy Body-Like Symptoms in Normal Controls, Mild Cognitive Impairment, and Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 43, 1007-1016.	1.2	27
200	Association of brain amyloid-Î² with cerebral perfusion and structure in Alzheimerâ€™s disease and mild cognitive impairment. Brain, 2014, 137, 1550-1561.	3.7	150
201	Altered Cerebrospinal Fluid Levels of Amyloid Î² and Amyloid Precursor-Like Protein 1 Peptides in Downâ€™s Syndrome. NeuroMolecular Medicine, 2014, 16, 510-516.	1.8	28
202	The cerebrospinal fluid â€œAlzheimer profileâ€: Easily said, but what does it mean?. Alzheimer's and Dementia, 2014, 10, 713.	0.4	249
203	Automated cerebrospinal fluid cell count â€” New reference ranges and evaluation of its clinical use in central nervous system infections. Clinical Biochemistry, 2014, 47, 25-30.	0.8	22
204	Effects of cerebrospinal fluid proteins on brain atrophy rates in cognitively healthy older adults. Neurobiology of Aging, 2014, 35, 614-622.	1.5	42
205	Smoking and increased Alzheimer's disease risk: A review of potentialÂmechanisms. Alzheimer's and Dementia, 2014, 10, S122-45.	0.4	285
206	Bidirectional links between Alzheimer's disease and Niemannâ€“Pick type C disease. Neurobiology of Disease, 2014, 72, 37-47.	2.1	68
207	CSF biomarkers for Alzheimerâ€™s pathology and the effect size of APOE É›4. Molecular Psychiatry, 2014, 19, 148-149.	4.1	30
208	P4-137: THE TRANSITIONAL ASSOCIATION BETWEEN BETA-AMYLOID PATHOLOGY AND REGIONAL BRAIN ATROPHY. , 2014, 10, P837-P838.		3
209	Cerebrospinal Fluid Biomarkers in Alzheimerâ€™s Disease and Frontotemporal Dementia. , 2014, , 131-157.		0
210	The influence of disease duration, clinical course, and immunosuppressive therapy on the synthesis of intrathecal oligoclonal IgG bands in multiple sclerosis. Journal of Neuroimmunology, 2013, 264, 100-105.	1.1	30
211	CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimer's and Dementia, 2013, 9, 251-261.	0.4	344
212	Serum but not cerebrospinal fluid levels of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3) are increased in Alzheimer's disease. Psychoneuroendocrinology, 2013, 38, 1729-1737.	1.3	66
213	Coagulation of cerebrospinal fluidâ€”the Nonneâ€“Froin sign. Practical Neurology, 2013, 13, 273-274.	0.5	1
214	Cerebrospinal fluid biomarkers in neurological diseases inÂchildren. European Journal of Paediatric Neurology, 2013, 17, 7-13.	0.7	18
215	Cerebrospinal Fluid Brain Injury Biomarkers in Children: A Multicenter Study. Pediatric Neurology, 2013, 49, 31-39.e2.	1.0	33
216	Reduced cerebrospinal fluid level of thyroxine in patients with Alzheimer's disease. Psychoneuroendocrinology, 2013, 38, 1058-1066.	1.3	38

#	Article	IF	Citations
217	Cerebrospinal fluid CXCL13 in Lyme neuroborreliosis and asymptomatic HIV infection. BMC Neurology, 2013, 13, 2.	0.8	49
218	Global standardization measurement of cerebral spinal fluid for Alzheimer's disease: An update from the Alzheimer's Association Global Biomarkers Consortium. Alzheimer's and Dementia, 2013, 9, 137-140.	0.4	105
219	Cerebrospinal fluid biomarkers of Î²-amyloid metabolism in multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 543-552.	1.4	43
220	Serum levels of LIGHT in MS. Multiple Sclerosis Journal, 2013, 19, 871-876.	1.4	17
221	Cerebrospinal fluid analyses for the diagnosis of subarachnoid haemorrhage and experience from a Swedish study. What method is preferable when diagnosing a subarachnoid haemorrhage?. Clinical Chemistry and Laboratory Medicine, 2013, 51, 2073-2086.	1.4	37
222	CSF protein biomarkers predicting longitudinal reduction of CSF Î²-amyloid42 in cognitively healthy elders. Translational Psychiatry, 2013, 3, e293-e293.	2.4	51
223	Cerebrospinal fluid biomarkers for Alzheimer disease and subcortical axonal damage in 5,542 clinical samples. Alzheimer's Research and Therapy, 2013, 5, 47.	3.0	37
224	Plasma Amyloid-Î² in Patients with Tangier Disease. Journal of Alzheimer's Disease, 2013, 35, 307-312.	1.2	3
225	Journal Watch: Our panel of experts highlight the most important research articles across the spectrum of topics relevant to the field of neurodegenerative disease management. Neurodegenerative Disease Management, 2013, 3, 105-107.	1.2	0
226	Journal Watch: Our panel of experts highlight the most important research articles across the spectrum of topics relevant to the field of neurodegenerative disease management.. Neurodegenerative Disease Management, 2013, 3, 19-21.	1.2	0
227	Cerebrospinal Fluid (CSF) 25-Hydroxyvitamin D Concentration and CSF Acetylcholinesterase Activity Are Reduced in Patients with Alzheimer's Disease. PLoS ONE, 2013, 8, e81989.	1.1	45
228	Effects of Baseline CSF Î±-Synuclein on Regional Brain Atrophy Rates in Healthy Elders, Mild Cognitive Impairment and Alzheimerâ€™s Disease. PLoS ONE, 2013, 8, e85443.	1.1	16
229	The Accu-Chek Mobile blood glucose monitoring system used under controlled conditions meets ISO 15197 standards in the hands of diabetes patients. Scandinavian Journal of Clinical and Laboratory Investigation, 2012, 72, 374-379.	0.6	9
230	What is a certified reference material?. Biomarkers in Medicine, 2012, 6, 369-370.	0.6	11
231	Journal Watch: Our panel of experts highlight the most important research articles across the spectrum of topics relevant to the field of neurodegenerative disease management. Neurodegenerative Disease Management, 2012, 2, 451-453.	1.2	0
232	Journal Watch: Our panel of experts highlight the most important research articles across the spectrum of topics relevant to the field of neurodegenerative disease management. Neurodegenerative Disease Management, 2012, 2, 569-572.	1.2	0
233	Journal Watch: Our experts highlight the most important research articles across the spectrum of topics relevant to the field of neurodegenerative disease management. Neurodegenerative Disease Management, 2012, 2, 351-354.	1.2	1
234	Longitudinal Cerebrospinal Fluid Biomarkers over Four Years in Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2012, 30, 767-778.	1.2	76

#	Article	IF	Citations
235	Mass Spectrometric Characterization of Amyloid-Î² Species in the 7PA2 Cell Model of Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 33, 85-93.	1.2	48
236	Age and diagnostic performance of Alzheimer disease CSF biomarkers. Neurology, 2012, 78, 468-476.	1.5	154
237	Amyloid-Î² metabolism in Niemann-Pick C disease models and patients. Metabolic Brain Disease, 2012, 27, 573-585.	1.4	39
238	Determining cut-points for Alzheimerâ€™s disease biomarkers: statistical issues, methods and challenges. Biomarkers in Medicine, 2012, 6, 391-400.	0.6	52
239	Reference measurement procedures for Alzheimerâ€™s disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid Î²42. Biomarkers in Medicine, 2012, 6, 409-417.	0.6	76
240	Proficiency testing programs for Alzheimerâ€™s disease cerebrospinal fluid biomarkers. Biomarkers in Medicine, 2012, 6, 401-407.	0.6	24
241	Peptidome Analysis of Cerebrospinal Fluid by LC-MALDI MS. PLoS ONE, 2012, 7, e42555.	1.1	57
242	An online nanoâ€LCâ€ESIâ€FTICRâ€MS method for comprehensive characterization of endogenous fragments from amyloid Î² and amyloid precursor protein in human and cat cerebrospinal fluid. Journal of Mass Spectrometry, 2012, 47, 591-603.	0.7	78
243	Cerebrospinal fluid biomarkers to monitor treatment effects in Alzheimerâ€™s disease and related conditions. Neurodegenerative Disease Management, 2012, 2, 117-123.	1.2	0
244	Cerebrospinal Fluid Profiles of Amyloid Î²-Related Biomarkers in Alzheimerâ€™s Disease. NeuroMolecular Medicine, 2012, 14, 65-73.	1.8	70
245	Leukocyte Telomere Length (LTL) is reduced in stable mild cognitive impairment but low LTL is not associated with conversion to Alzheimer's Disease: A pilot study. Experimental Gerontology, 2012, 47, 179-182.	1.2	44
246	BACE1 Inhibition Induces a Specific Cerebrospinal Fluid Î²-Amyloid Pattern That Identifies Drug Effects in the Central Nervous System. PLoS ONE, 2012, 7, e31084.	1.1	68
247	CSF biomarkers in neurodegenerative diseases. Clinical Chemistry and Laboratory Medicine, 2011, 49, 345-352.	1.4	56
248	Î³-Secretase-dependent amyloid-Î² is increased in Niemann-Pick type C. Neurology, 2011, 76, 366-372.	1.5	62
249	The N-terminal domain of Î±-dystroglycan, released as a 38kDa protein, is increased in cerebrospinal fluid in patients with Lyme neuroborreliosis. Biochemical and Biophysical Research Communications, 2011, 412, 494-499.	1.0	11
250	The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimer's and Dementia, 2011, 7, 386.	0.4	354
251	Biomarkers for Microglial Activation in Alzheimer's Disease. International Journal of Alzheimer's Disease, 2011, 2011, 1-5.	1.1	23
252	Discriminatory Analysis of Biochip-Derived Protein Patterns in CSF and Plasma in Neurodegenerative Diseases. Frontiers in Aging Neuroscience, 2011, 3, 1.	1.7	73

#	Article	IF	Citations
253	Novel AβIsoforms in Alzheimer's Disease - Their Role in Diagnosis and Treatment. Current Pharmaceutical Design, 2011, 17, 2594-2602.	0.9	66
254	Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: Diagnostic Performance in a Homogeneous Mono-Center Population. Journal of Alzheimer's Disease, 2011, 24, 537-546.	1.2	68
255	Mild dementia is associated with increased adrenal secretion of cortisol and precursor sex steroids in women. Clinical Endocrinology, 2011, 75, 301-308.	1.2	10
256	Cerebrospinal Fluid Microglial Markers in Alzheimerâ€™s Disease: Elevated Chitotriosidase Activity but Lack of Diagnostic Utility. NeuroMolecular Medicine, 2011, 13, 151-159.	1.8	104
257	Miglustat Treatment May Reduce Cerebrospinal Fluid Levels of the Axonal Degeneration Marker Tau in Niemannâ€“Pick Type C. JIMD Reports, 2011, 3, 45-52.	0.7	25
258	Research Highlights. Biomarkers in Medicine, 2011, 5, 201-203.	0.6	0
259	A new member in the biomarker discovery toolbox. Biomarkers in Medicine, 2011, 5, 202.	0.6	0
260	Troponin T: more than acute myocardial infarction. Biomarkers in Medicine, 2011, 5, 203.	0.6	0
261	Growth factors in Parkinson's disease. Biomarkers in Medicine, 2011, 5, 201-2.	0.6	0
262	It is all about clearance. Biomarkers in Medicine, 2011, 5, 202.	0.6	0
263	To Know or Not to Know: Ethical Issues Related to Early Diagnosis of Alzheimer's Disease. International Journal of Alzheimer's Disease, 2010, 2010, 1-4.	1.1	48
264	Cerebrospinal Fluid Analysis Should Be Considered in Patients with Cognitive Problems. International Journal of Alzheimer's Disease, 2010, 2010, 1-4.	1.1	6
265	Converging Pathways of Chromogranin and Amyloid Metabolism in the Brain. Journal of Alzheimer's Disease, 2010, 20, 1039-1049.	1.2	19
266	Lessons from Multicenter Studies on CSF Biomarkers for Alzheimer's Disease. International Journal of Alzheimer's Disease, 2010, 2010, 1-5.	1.1	27
267	Inter-laboratory variation in cerebrospinal fluid biomarkers for Alzheimer's disease: united we stand, divided we fall. Clinical Chemistry and Laboratory Medicine, 2010, 48, 603-607.	1.4	78
268	Neuroinflammation in Lyme neuroborreliosis affects amyloid metabolism. BMC Neurology, 2010, 10, 51.	0.8	49
269	Converging molecular pathways in human neural development and degeneration. Neuroscience Research, 2010, 66, 330-332.	1.0	34
270	Proteomic profiling of cerebrospinal fluid in parkinsonian disorders. Parkinsonism and Related Disorders, 2010, 16, 545-549.	1.1	38

#	Article	IF	Citations
271	Biochemical markers in Alzheimerâ€™s disease clinical trials. Biomarkers in Medicine, 2010, 4, 91-98.	0.6	14
272	Use of theragnostic markers to select drugs for phase II/III trials for Alzheimer disease. Alzheimer's Research and Therapy, 2010, 2, 32.	3.0	15
273	Future Screening for Incipient Alzheimerâ€™s Disease â€“ The Influence of Prevalence on Test Performance. European Neurology, 2009, 62, 200-203.	0.6	16
274	Alzheimerâ€™s disease and CSF biomarkers: key challenges for broad clinical applications. Biomarkers in Medicine, 2009, 3, 735-737.	0.6	24
275	Elevated cerebrospinal fluid levels of prostaglandin E2 and 15‹i›â€(S)â€‹/i›hydroxyeicosatetraenoic acid in multiple sclerosis. Journal of Internal Medicine, 2009, 265, 459-464.	2.7	28
276	CSF Biomarkers. Annals of the New York Academy of Sciences, 2009, 1180, 28-35.	1.8	60
277	Reduced cerebrospinal fluid BACE1 activity in multiple sclerosis. Multiple Sclerosis Journal, 2009, 15, 448-454.	1.4	55
278	CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment. JAMA - Journal of the American Medical Association, 2009, 302, 385.	3.8	1,009
279	Novel cerebrospinal fluid biomarkers of axonal degeneration in frontotemporal dementia. Molecular Medicine Reports, 2008, 1, 757-61.	1.1	26
280	Elevated cerebrospinal fluid F2-isoprostane levels indicating oxidative stress in healthy siblings of multiple sclerosis patients. Neuroscience Letters, 2007, 414, 233-236.	1.0	33
281	Intra-Individual Stability of CSF Biomarkers for Alzheimer's Disease over Two Years. Journal of Alzheimer's Disease, 2007, 12, 255-260.	1.2	117
282	Cerebrospinal fluid concentrations of peptides derived from chromogranin B and secretogranin II are decreased in multiple sclerosis. Journal of Neurochemistry, 2007, 103, 1932-1939.	2.1	29
283	Discontinuation of proton pump inhibitors in patients on long-term therapy: a double-blind, placebo-controlled trial. Alimentary Pharmacology and Therapeutics, 2006, 24, 945-954.	1.9	155